1. Signature of strategic cooperation by three parties 
On October 8, 2023, under the witness of leaders of Taizhou Pharmaceutical High-tech Industrial Park, Jiangsu Recbio Technology Co., Ltd., Zimbabwe National Biotechnology Authority and ICGEB-China Regional Research Center jointly signed a strategic cooperation agreement. According to the agreement, Recbio will cooperate with the Regional Research Center to provide technical support related to vaccine production in Zimbabwe. take the COVID-19 vaccine as the starting point to gradually expand to other vaccine varieties, and contribute to the localization of vaccine production in Zimbabwe and Africa. This cooperation is not only another cooperation achievement of the "Belt and Road" Initiative in the African continent, but also a new start for Taizhou and Zimbabwe to work together in the field of big health. After signature of the agreement, the three parties were received by the leaders of Taizhou Municipal Government and Taizhou Pharmaceutical High-Tech Zone (Gaogang District).

2. The start of ICGEB International Vaccine Forum Three Months Ago
In July 2023, to enhance Sino-foreign exchanges and cooperation in vaccine science and technology, the Regional Research Center held the ICGEB 2023 International Forum on Cutting-edge Vaccine Technology and Application. The National Biotechnology Administration of Zimbabwe (one of 68 member countries of ICGEB) applied to attend the conference in China Medical City. After the meeting, National Biotechnology Authority of Zimbabwe established friendly and close ties with the Regional Research Center, hoping that the center could help it realize its desire to introduce Chinese vaccine technology and fill the gaps in its domestic vaccine production.

3. Zimbabwe’s three times of visit to China to deepen cooperation
In August 2023, the National Biotechnology Authority of Zimbabwe visited the Regional Research Center twice, and visited and investigated some vaccine enterprises in China Medical City, such as Jiangsu Recbio and Sinovet Biological, under the help of the Regional research Center, to learn about the relevant vaccine enterprises in detail. In September 2023, the Regional Research Center welcomed the National Biotechnology Authority of Zimbabwe for three visits, facilitating the substantive negotiation and cooperation between Jiangsu Recbio Biotechnology Co., Ltd. and the National Biotechnology Authority of Zimbabwe. Subsequently, Recbio passed the GMP compliance inspection of the Zimbabwe MCAZ team, met the requirements of the introduction of pharmaceutical products and technology transfer in Zimbabwe, and then signed the tripartite cooperation agreement.

4. Prospects for future cooperation
With the COVID-19 vaccine as the starting point, this cooperation will promote China Medical City vaccine enterprises to go abroad and seize the overseas market layout of vaccines. The follow-up cooperation will expand to other vaccine varieties. With the gradual deepening of cooperation between China Medical City enterprises and Zimbabwe, it is expected to achieve more cooperation results in pharmaceutical and other fields. The China Medical City enterprises, represented by Rekbio, will comprehensively propel the development of vaccine production technology in Zimbabwe from personnel training, plant design, clinical trials, sub-packaging technology transfer and stock solution technology transfer, help it achieve localized vaccine production, better improve the livelihood of Zimbabwean people, and realize long-term win-win cooperation.

The National Biotechnology Authority of Zimbabwe is a government agency established by legislation in 2006,to promote the application of traditional and cutting-edge biotechnology in the fields such as medicine and agriculture.

Jiangsu Recbio Technology Co., Ltd. (hereinafter referred to as Recbio or the Enterprise; stock code: 2179.HK), founded in 2012, is an innovative vaccine enterprise with independent research and development technology as the core driving force. It is committed to creating innovative vaccines covering the research and development, production and commercialization of cervical cancer, herpes zoster, COVID-19 and other diseases with a major burden.